

Data Sharing Statement

Article Info	http://dx.doi.org/10.21037/jtd-20-755.	
Item	Question	Authors' Response (place "-" if not applicable)
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	The survival data and the association between anlotinib and PNI will be shared, which has seldom been reported in previous studies
4	Any other documents will be share? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan will be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	Two years within the publication date, since the survival date may be updated over time.
7	To whom will you share the data?	Medical oncologists who are interested in the treatment of lung cancer.
8	For what type of analysis or purpose?	For analysis to explore the correlation between pretreatment PNI and survival in patients with extensive stage SCLC (ES-SCLC) treated with anlotinib.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: wangchangli309@163.com , or chengying@cscsco.org.cn
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.